FDA Approves First Orexin Agonist for Narcolepsy Type 1

AIMode News Desk · curated summary

August 21, 20261 min readHealth

Automated news aggregation. Headlines and summaries are gathered from public feeds; see our editorial standards for sourcing, corrections, and AI-assist disclosure.

Related coverage: FDA Approves First Orexin Agonist for Narcolepsy Type 1 The American Journal of Managed Care

About this story

This story was aggregated from The American Journal of Managed Care. Headlines, summaries, and links are gathered automatically from public RSS feeds for your convenience.

Read the full story →

For agents:JSON record OpenAPI WebMCP llms.txt

FDA Approves First Orexin Agonist for Narcolepsy Type 1

About this story

More in Health

Ultragenyx Receives Accelerated FDA Approval For Metabolic Gene Therapy

Molecular Switch Driving Triple-Negative Breast Cancer Metastasis Identified

First-in-class therapy targets “undruggable” protein in hard-to-treat blood cancers | Newswise

Australian researchers uncover a promising new way to tackle triple-negative breast cancer